Lupin Ltd. Upgraded to Strong Buy on Robust Valuation and Financial Performance

Valuation Upgrade: From Attractive to Very Attractive

The primary catalyst for Lupin’s rating upgrade is its enhanced valuation profile. The company’s price-to-earnings (PE) ratio currently stands at 19.01, which is notably lower than several peers such as Zydus Lifesciences (PE 20.48) and Aurobindo Pharma (PE 25.45), signalling a more reasonable entry point for investors. Additionally, Lupin’s price-to-book value is 4.88, reflecting a discount relative to its sector counterparts.

Enterprise value multiples further reinforce this attractive valuation. The EV to EBITDA ratio is 12.13, well below the likes of Mankind Pharma at 29.62 and Laurus Labs at 46.86, indicating that Lupin is trading at a more conservative multiple relative to its earnings before interest, tax, depreciation, and amortisation. The PEG ratio, a key measure of valuation relative to growth, is exceptionally low at 0.25, underscoring the stock’s undervaluation given its earnings growth prospects.

Dividend yield remains modest at 0.50%, consistent with the company’s reinvestment strategy to fuel growth. Overall, these valuation metrics have shifted Lupin’s grade from “attractive” to “very attractive,” signalling enhanced upside potential for investors.

Financial Trend: Strong Growth and Profitability

Lupin’s financial performance continues to impress, with the company reporting very positive results for the fourth quarter of FY25-26. Net sales for the quarter reached a record ₹7,474.66 crores, reflecting a robust annual growth rate of 13.02%. Operating profit margins have expanded to 34.70%, while net profit surged by 24.41%, marking the fourth consecutive quarter of positive earnings growth.

Return on capital employed (ROCE) has reached a half-year high of 27.06%, and return on equity (ROE) stands at an impressive 25.68%. These figures highlight Lupin’s efficient capital utilisation and strong profitability, which underpin the company’s upgraded financial trend rating. The company’s debt-to-equity ratio remains conservative at 0.11 times, indicating a healthy balance sheet with limited leverage risk.

Over the past year, Lupin’s stock has delivered a 21.77% return, outperforming the BSE Sensex which declined by 8.09% over the same period. This outperformance is supported by a 75.6% increase in profits, further validating the company’s strong financial momentum.

Quality Assessment: Robust Operational and Market Position

Lupin’s quality metrics remain strong, contributing to its elevated Mojo Score of 80.0 and a Mojo Grade upgrade to Strong Buy from Buy. The company is recognised among the top 1% of over 4,000 stocks rated by MarketsMojo, reflecting its superior fundamentals and consistent operational excellence.

Key quality indicators include a low debt-to-equity ratio of 0.11 times, which minimises financial risk, and a high institutional holding of 47.03%, signalling confidence from sophisticated investors with deep analytical capabilities. Lupin’s consistent track record of positive quarterly results and strong return ratios further reinforce its quality credentials.

Moreover, Lupin’s stock has demonstrated remarkable consistency in returns, generating 165.48% over three years compared to the Sensex’s 18.86%, and 109.07% over five years versus the Sensex’s 47.03%. This sustained outperformance highlights the company’s ability to deliver shareholder value over the long term.

Technical Outlook: Stable Price Action with Upside Potential

Technically, Lupin’s stock price has shown resilience despite a minor day decline of 0.98% to ₹2,396.50 on 2 July 2026. The stock remains close to its 52-week high of ₹2,492.00, with a 52-week low of ₹1,838.65, indicating a strong trading range and investor interest.

Price momentum is supported by positive returns across multiple timeframes: 1.21% over one week, 6.04% over one month, and a notable 13.47% year-to-date gain, all outperforming the Sensex benchmarks. This technical strength complements the fundamental upgrades, suggesting that the stock is well-positioned for further appreciation.

Investors should note that Lupin’s valuation discount relative to peers, combined with its robust financial and quality metrics, provides a favourable risk-reward profile from a technical perspective.

Comparative Industry Positioning and Market Cap Considerations

Within the Pharmaceuticals & Biotechnology sector, Lupin’s mid-cap status and valuation metrics place it favourably against peers. While companies like Mankind Pharma and Laurus Labs trade at significantly higher multiples, Lupin’s conservative valuation and strong growth trajectory offer a more balanced investment proposition.

The company’s return on capital employed of 37.51% and return on equity of 25.68% are among the highest in the sector, underscoring operational efficiency and effective capital deployment. These factors, combined with a PEG ratio of 0.25, indicate that Lupin’s earnings growth is not fully priced in by the market, justifying the upgrade to Strong Buy.

Investors should also consider Lupin’s consistent dividend policy and strong institutional backing, which provide additional confidence in the stock’s stability and growth prospects.

Outlook and Investment Implications

Lupin Ltd.’s upgrade to a Strong Buy rating by MarketsMojo reflects a comprehensive improvement across valuation, financial trends, quality, and technical parameters. The company’s very attractive valuation, robust profitability, and consistent growth trajectory position it well for continued outperformance in the Pharmaceuticals & Biotechnology sector.

While the stock experienced a slight dip on 2 July 2026, its long-term fundamentals and technical momentum remain intact. Investors seeking exposure to a fundamentally strong mid-cap pharmaceutical stock with a proven track record of delivering shareholder value should consider Lupin as a core portfolio holding.

Given the company’s strong institutional support and favourable market positioning, Lupin is poised to benefit from both sectoral tailwinds and internal growth drivers in the coming quarters.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today